Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 16 | 2026 | 610 | 3.120 |
Why?
|
| Transplantation, Autologous | 8 | 2019 | 488 | 0.930 |
Why?
|
| Graft vs Host Disease | 2 | 2022 | 93 | 0.780 |
Why?
|
| Transplantation Conditioning | 5 | 2026 | 96 | 0.660 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2020 | 11 | 0.640 |
Why?
|
| Calcineurin | 1 | 2020 | 76 | 0.600 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 101 | 0.590 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 177 | 0.520 |
Why?
|
| Multiple Myeloma | 4 | 2019 | 3082 | 0.520 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 188 | 0.510 |
Why?
|
| Hepatitis B Antibodies | 1 | 2017 | 7 | 0.510 |
Why?
|
| Virus Activation | 1 | 2017 | 49 | 0.490 |
Why?
|
| Pandemics | 1 | 2020 | 595 | 0.470 |
Why?
|
| Roseolovirus Infections | 2 | 2022 | 3 | 0.370 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2022 | 9 | 0.360 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2026 | 208 | 0.350 |
Why?
|
| Humans | 20 | 2026 | 53230 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2026 | 34 | 0.240 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2026 | 87 | 0.230 |
Why?
|
| Incidence | 2 | 2020 | 1085 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2026 | 238 | 0.210 |
Why?
|
| HLA Antigens | 1 | 2024 | 55 | 0.210 |
Why?
|
| Aged | 8 | 2026 | 10429 | 0.200 |
Why?
|
| Herpesvirus 6, Human | 1 | 2022 | 3 | 0.190 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2022 | 3 | 0.190 |
Why?
|
| Tissue Donors | 2 | 2024 | 130 | 0.190 |
Why?
|
| Tacrolimus | 2 | 2021 | 61 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1043 | 0.190 |
Why?
|
| Hyponatremia | 1 | 2022 | 13 | 0.190 |
Why?
|
| Retrospective Studies | 6 | 2022 | 6819 | 0.190 |
Why?
|
| Middle Aged | 9 | 2022 | 13419 | 0.180 |
Why?
|
| Propensity Score | 2 | 2019 | 170 | 0.180 |
Why?
|
| Blast Crisis | 1 | 2021 | 5 | 0.170 |
Why?
|
| Melphalan | 2 | 2019 | 180 | 0.170 |
Why?
|
| Pain | 2 | 2021 | 351 | 0.170 |
Why?
|
| Myeloproliferative Disorders | 1 | 2021 | 31 | 0.170 |
Why?
|
| Ascites | 1 | 2020 | 31 | 0.160 |
Why?
|
| Cyclosporine | 1 | 2020 | 64 | 0.160 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2019 | 6 | 0.160 |
Why?
|
| Chromosomes | 1 | 2019 | 28 | 0.160 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 154 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2019 | 56 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2019 | 76 | 0.150 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2019 | 38 | 0.150 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 191 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 266 | 0.150 |
Why?
|
| Vincristine | 1 | 2018 | 89 | 0.140 |
Why?
|
| Myeloablative Agonists | 1 | 2018 | 32 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2018 | 659 | 0.140 |
Why?
|
| POEMS Syndrome | 1 | 2018 | 34 | 0.140 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 110 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 445 | 0.140 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 59 | 0.140 |
Why?
|
| Prednisone | 1 | 2018 | 101 | 0.140 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 78 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2019 | 5595 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 253 | 0.140 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 65 | 0.140 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 178 | 0.140 |
Why?
|
| Translocation, Genetic | 1 | 2019 | 266 | 0.140 |
Why?
|
| Male | 10 | 2026 | 27435 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2020 | 1557 | 0.120 |
Why?
|
| Female | 10 | 2026 | 28782 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2015 | 83 | 0.110 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2015 | 90 | 0.110 |
Why?
|
| Whole-Body Irradiation | 2 | 2026 | 129 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1212 | 0.100 |
Why?
|
| Survival Rate | 3 | 2021 | 949 | 0.090 |
Why?
|
| Adult | 5 | 2019 | 14534 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2021 | 466 | 0.070 |
Why?
|
| Maintenance Chemotherapy | 2 | 2019 | 52 | 0.070 |
Why?
|
| Remission Induction | 2 | 2019 | 221 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 640 | 0.060 |
Why?
|
| Vidarabine | 1 | 2026 | 10 | 0.060 |
Why?
|
| Histocompatibility Testing | 1 | 2024 | 14 | 0.050 |
Why?
|
| Isoantibodies | 1 | 2024 | 26 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2024 | 166 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 206 | 0.050 |
Why?
|
| Foscarnet | 1 | 2022 | 2 | 0.050 |
Why?
|
| Viremia | 1 | 2022 | 23 | 0.050 |
Why?
|
| Podophyllotoxin | 1 | 2019 | 3 | 0.040 |
Why?
|
| Carmustine | 1 | 2019 | 12 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 48 | 0.040 |
Why?
|
| Cytarabine | 1 | 2019 | 44 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2018 | 12 | 0.040 |
Why?
|
| Pyrazines | 1 | 2019 | 188 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2018 | 63 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 487 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 694 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2018 | 234 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 774 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1136 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 2118 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2318 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 3494 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 6907 | 0.020 |
Why?
|